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Abstract
Background: The cost effective treatment of cancer in developing countries remains challenging.
In the elderly with possible limited life expectancy, the health expenditure associated with standard
treatment regimes should be carefully considered. We present the results of conservative
management of breast cancer in the aged in a resource-limited environment.
Methods: Patients aged 70 or older with early breast cancer were treated with tumour excision
or simple mastectomy and adjuvant tamoxifen. The records of patients presenting to the Breast
Unit between January 1990 and December 2004 were retrieved and demographic, clinical,
pathological and oncological data were reviewed. Survival statistics were calculated using the life
table method.
Results: A total of 483 patients above 70 years of age were identified. One hundred and eighty
eight patients were managed according to the conservative protocol. Forty-one had a simple
mastectomy and 147 tumour excision. Their mean age was 77.3 years. The mean follow-up is 62
months. Thirty-one patients (16.4%) were not compliant with tamoxifen use. TNM staging was 0
in 4 patients, I in 42 patients, II in 116 patients and III in 26 patients. There was no 30-day mortality.
The cumulative incidence of local recurrence was 3.3% at 5 and 10 years. The cumulative incidence
of regional recurrence was 3.3% at 5 years and 4.5% at 10 years. The cumulative incidence of distant
recurrence was 6.2% at 5 years and 12.2% at 10 years. The cumulative overall, disease specific and
disease free survival at 10 years was 59%, 88% and 81% respectively.
Conclusion: Limited surgery and tamoxifen provide excellent control of breast cancer in the
elderly in a resource restricted environment. Radiotherapy and axillary dissection and can be safely
omitted thereby reducing health care resource utilization.
Background
The treatment of breast cancer in the elderly is controver-
sial [1-6]. The life expectancy of elderly patients in devel-
oping countries may be less than in developed countries
[7] and the health expenditure associated with standard
treatment regimes should be carefully considered.
Some authors from developed countries recommend less
aggressive options in the elderly [2,8,9], while others
advocate standard treatment for all patients regardless of
age [3,5,9].
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cancers and special histopathological subtypes associated
with a favourable prognosis increases [8]. The potential
for local recurrence decreases with age [10-12].
Due to these factors and an increased death rate from con-
comitant disease, it may be possible to avoid the morbid-
ity associated with axillary dissection and radiotherapy in
the elderly without increasing the risk of local and
regional recurrence and survival [10,12-16].
We present here an update of a prior audit of conservative
management of breast cancer in the aged in a resource-
limited environment [17] with emphasis on the relation-
ship of pathological data to patterns of local and distant
failure. To our knowledge this is the only data on breast
cancer outcomes in similar circumstances.
Methods
In patients aged 70 or older, tumour excision or simple
mastectomy for small breasts and adjuvant tamoxifen for
oestrogen receptor positive tumours was performed.
Patients with oestrogen receptor positive T3 and T4b
lesions are considered for neo-adjuvant tamoxifen in an
attempt to shrink the tumour before surgery. Neither radi-
otherapy nor axillary dissection is offered, even in patients
with N1 nodal status.
The records of 483 women aged 70 or older at the time of
diagnosis that had presented to the Breast Unit between
January 1990 and December 2004 were reviewed. The
records of patients that were treated with limited surgery
and tamoxifen were analyzed for the variables summa-
rized in Table 1. Data were collected from a prospective
breast cancer database.
Clinical staging was according to the sixth edition of the
Union International Contre le Cancer/American Joint
Committee on Cancer TNM classification manual[18].
Resection of all gross tumour was performed in all
patients. Tumours were analyzed for the pathological var-
iables summarized in Table 1. Due to resource restric-
tions, hormone receptor and c-erb B2 status were not
determined at our institution before March 2004. Conse-
quently, these variables are only known on a few elderly
patients with early breast cancer.
Telephone follow-up was conducted for all patients not
seen at the hospital within the preceding 6 months.
Deceased patients were classified as either dead from dis-
ease or dead of other causes based on information from
the primary care physician, caregivers or family members.
Survival statistics were calculated using the life table
method [19].
Results
Out of a total of 3681 patients diagnosed with breast can-
cer at Tygerberg Hospital, 483 patients were above 70
years of age. Two hundred and thirty three tumours (48%)
were considered too advanced for the protocol. Of these,
eight had stage IIA disease, 20 had Stage IIB disease, and
22 had stage IIIA disease, 75 had stage IIIB disease and
108 patients presented with stage IV disease. Of the 125
patients with stage II and III disease, 85 were excluded due
to bulky axillary disease requiring a full axillary dissection
and 40 due to the advanced nature of their breast lesions
requiring radiation therapy for local control. Thirty five
patients (7.2%) were considered too frail for any surgery.
In nine (1.9%) patients other treatment options were cho-
sen: One patient had palpable axillary nodes and received
a full axillary clearance as due to extremely poor socio-
economic circumstances compliance with a regular fol-
low-up regime was impossible. Four patients were par-
tially treated elsewhere before referral to our centre. One
patient had postoperative radiation for a multicentric
tumour. One patient requested a modified radical mastec-
tomy. Two patients had squamous cell carcinomas and
were excluded from the study. Fourteen patients had
either postoperative radiotherapy (2 patients) or a modi-
fied radical mastectomy as part of international multi-
center trials. Four patients refused surgery. One hundred
and eighty eight patients were treated according to the
protocol. Forty-one had a simple mastectomy (SM) and
147 tumour excisions (TE).
Age ranged from 70 to 95 years. The mean age was 77.3
years. Associated co-morbidities were common with a
mean of 1.4 co morbidities per patient. Table 2 and 3
reflect these co morbidities.
Table 1: Data collected
Clinical
Co-morbidity
TNM staging
Treatment
Early mortality
Compliance with tamoxifen
Histopathology
Pathological size in millimetres
Histological grading [51]
Evidence and extent of ductal carcinoma in situ
Evidence of lymphovascular infiltration
Resection margins (clear = >3 mm, 
marginal = 1–3 mm, involved = <1 mm)
Survival data
Time to local, regional, or distant recurrence
Current status
Disease-free survival
Disease specific survival
Overall survivalPage 2 of 8
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Table 4 and 5.
Twenty-one patients (14%) treated by TE and ten patients
(24%) treated by SM had small, mobile nodes palpable.
The World Health Organization tumour types are
reflected in Table 6[20]. Grossly tumour free margins were
achieved in all patients. In 126 patients, histopathological
margins were more than 3 mm. In 38 patients, margins
were less than 3 mm and in 24 patients resection margins
were involved with tumour on microscopic examination;
no further resections were performed to achieve tumour
free margins. The mean tumour size for patients who had
a TE was 22.2 mm (range: 5–70 mm) and 47.25 mm for
those who had a simple mastectomy (range: 10–150
mm).
One hundred tumours (53%) had no in situ component.
Thirty four tumours had extensive ductal carcinoma in
situ, 24 in the TE group and ten in the SM group. Lym-
phovascular infiltration was detected in 16 (9%) of
tumours. There was no 30-day mortality.
The mean follow-up for the entire group is 62 months
(range 4 to 166 months). Five are alive with evidence of
disease at 43, 62, 75, 95 and 128 months respectively.
Twenty patients have died of breast cancer, 93 are alive
with no evidence of disease, and 53 have died of other dis-
eases. Of the 188 patients, 17 are lost to follow-up. Thirty-
one patients (16.4%) were not compliant with tamoxifen
use.
None of the patients who had a SM and 6 patients with a
TE suffered a local recurrence. In four of these patients dis-
ease was controlled with a further local excision at 7, 23,
27 and 50 months after initial treatment. Two of these
patients have died of intercurrent illnesses. They were dis-
ease free at the time of death. The other two patients are
alive and well with no evidence of disease at 55 and 62
months after initial treatment. One patient's local recur-
rence was controlled with radiotherapy 8 months after ini-
tial treatment. The patient is alive with no evidence of
disease at 43 months. One patient had concurrent
regional metastases and was treated by mastectomy with
axillary dissection at 55 months. This patient went on to
develop distant metastases at 86 months and died of
breast cancer at 166 months.
All 6 patients had infiltrating ductal carcinoma. In 3
patients resection margins were clear. In 2 they were mar-
ginal and in 1 the margins were involved. The patient with
involved margins developed a recurrence at 8 months
after initial surgery and is discussed above. None of the
patients with local recurrence had tumours with an exten-
sive in situ component.
The patient that also developed regional and distant
metastasis had a grade 2 infiltrating ductal carcinoma
with lymphovascular infiltration. None of the other
patients with local recurrence had tumours with lym-
Table 5: TNM- stage of tumours
TNM- stage Number of Patients %
0 4 2%
I 42 22%
II 116 62%
III 26 14%
Table 3: Number of co morbidities per patient
Number of Co morbidities Number of Patients
5 1
4 4
3 16
2 59
1 73
Table 2: Number of patients with co morbidities
Co morbidities Number of Patients
Hypertension 117
Heart disease 54
Diabetes Mellitus 28
Pulmonary disease 7
Renal disease 2
Stroke 8
Other malignancy 22
Dementia 5
Arthritis 2
Hypothyroidism 3
Schizophrenia 1
Peripheral vascular disease 2
Table 4: T-stage of tumours
T- stage Tumour excision 
(n = 147)
Mastectomy 
(n = 41)
Tis 4 (3%) 0
T1b 10 (7%) 0
T1c 30 (22%) 3 (8%)
T2 85 (58%) 13 (33%)
T3 10 (7%) 12 (30%)
T4b 8 (5%) 13(33%)Page 3 of 8
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tumours was 14.8 mm (range 10 mm–20 mm)
None of the patients that were non compliant with
tamoxifen use developed a local recurrence.
The cumulative incidence of local recurrence is 3.3% at 5
and 10 years. The local control rate is reflected in Figure 1.
Regional recurrence developed in one patient who had a
SM at 47 months. Her recurrence was controlled by axil-
lary dissection. She developed distant metastases and died
67 months after initial diagnosis of breast cancer. Eight
patients who had a tumour excision developed regional
recurrence at 4, 19, 23, 35, 45, 55, 64 and 112 months
respectively. In 6 patients the recurrence was controlled by
axillary dissection. Two of these patients went on to
develop distant metastases. The one had a regional recur-
rence at 35 months and distant metastases at 96 months
and died shortly afterwards. The other patient was already
discussed. One patient refused axillary dissection when
she developed a regional recurrence at 23 months. She
died of intercurrent illness at 75 months. One patient was
considered too frail for any intervention when she devel-
oped regional recurrence at 112 months and died of inter-
current illness 7 months later. The other 4 are alive with
no evidence of disease. The cumulative incidence of
regional recurrence is 3.3% at 5 years and 4.5% at 10
years. The regional control rate is reflected in Figure 2.
None of the patients with palpable nodes at the time of
diagnosis required axillary dissection for regional control
during the course of their follow up. Two of the patients
that had a TE and suffered a local recurrence were not
compliant with tamoxifen use.
Distant metastases developed in 16 patients who had a TE
(10.8%) and in 5 patients who had a SM (12.2%) i.e. in
21 of the whole group. One patient developed bone
metastases at 83 months and is still alive with disease at
95 months after initial diagnosis; 20 died of metastatic
breast cancer. The cumulative incidence of distant recur-
rence is 6.2% at 5 years and 12.2% at 10 years. The distant
control rate is reflected in Figure 3.
Of the patients that developed distant recurrence, 15 had
infiltrating ductal carcinoma, three had papillary carci-
noma, two had mucinous carcinoma, and one had infil-
trating lobular carcinoma. Of the patients with infiltrating
ductal carcinoma, three had grade 1 tumours, ten had
grade 2 tumours and two had grade 3 tumours. One
patient that developed a distant recurrence was not com-
pliant with tamoxifen use.
The cumulative overall survival, disease specific survival
and disease free survival rates are reflected in Figures 4 to
6.
Discussion
In developed countries more than a third of all breast can-
cers occur in women over the age of 70 years [1,2,4]. In a
report from South Africa it is apparent that the disease is
seen at an earlier age in Blacks (mean 49 years) and Col-
oureds (mean 53 years) than in Whites (mean 60 years).
In this series 15% of Coloured patients, 5% of Black
Regional control rateFigure 2
Regional control rate.
Table 6: World Health Organization tumour type [20]
Type Number of Patients %
Ductal carcinoma in situ 4 2
Infiltrating ductal
Total 136 72
Grade 1 45 24
Grade 2 74 39
Grade 3 17 9
Infiltrating lobular 14 7
Mucinous 26 14
Papillary 6 3
Medullary 2 1
Local control rateFigure 1
Local control rate.Page 4 of 8
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years at presentation [21]. The population that we serve is
predominantly Coloured.
Breast cancer in the elderly is a more indolent disease than
in younger women [1,4,16]. In an analysis of the his-
topathological findings in 1869 post menopausal women
with breast cancer in a developed country, Fisher et al.,
demonstrated more favourable features with increasing
age. These features include less vascular invasion and lym-
phoplasmacytic stromal reaction. Elderly woman also
have a higher frequency of hormone receptor positive
tumours (85% oestrogen receptor positive versus 67% in
younger patients). Fifty eight percent (compared with
50%) were diagnosed with node negative disease
although 20% had tumours >5 cm (versus 13% of those
younger than 65). The incidence of grade 3 tumours also
decreased with age [8]. These results are comparable to the
low rates of lymphovascular invasion (9%) and grade 3
tumours (9%) in our series. In a series of 572 mastectomy
specimens of women of all ages from Pakistan, similar
pathological features were found as in western series of
non-screened populations [22].
The potential for local recurrence decreases with age [10-
12], an effect enhanced by tamoxifen [23]. The addition of
irradiation to partial mastectomy in younger patients
reduces the incidence of ipsilateral recurrence without
affecting survival [24-27].
In a large Italian series evaluating breast conservation in
women of all ages, radiotherapy did not improve local
control rates in patients over the age of 65 years [12]. The
results of three trials evaluating the role of radiotherapy in
early breast cancer in the elderly are summarized in Table
7. These results are comparable to our data.
Even in developed countries elderly women often do not
receive radiotherapy: In women older than 60 years
treated for stage I or II breast cancer with segmental mas-
tectomy, only 39.2% were referred for postoperative radi-
otherapy, whereas 82% of similar patients less than 60
years were referred. In elderly patients that received radia-
tion therapy, the complications were minimal. There was
a significant benefit of irradiation in achieving local and
regional control. The data even suggested that postopera-
tive irradiation may be more beneficial when extended to
elderly patients post segmental mastectomy than among
Disease free survivalFigure 6
Disease free survival.
Overall survivalFigure 4
Overall survival.
Distant control rateFigure 3
Distant control rate.
Disease specific survivalFigure 5
Disease specific survival.Page 5 of 8
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other series evaluating radiotherapy in the elderly and
these differences are difficult to explain. No analysis was
however done of factors other than age (i.e. co-morbidi-
ties, receptor status and tamoxifen use) as reasons for
referral for radiotherapy. A considerable number of
patients not referred for radiotherapy also had tumours
with unknown resection margin status [9].
In our patients the cumulative incidence of local recur-
rence is 3.3% at 5 and 10 years. It compares favourable to
reported local recurrence rates in younger patients receiv-
ing radiation after tumour excision [27-32]. This demon-
strates the value of appropriate patient selection. The
resection of infiltrated axillary nodes does not have a con-
trolling influence on survival but provides prognostic
information for planning post surgical therapy. A further
role for axillary dissection is that of regional control
[13,14,27,33,34].
Martelli et al., [13] reported on 321 elderly patients with
operable breast cancer and clinically non-palpable axil-
lary nodes randomised to surgery with (S+AD) or without
axillary dissection (S). All patients received tamoxifen.
There were no significant differences in overall or breast
cancer mortality or cumulative incidence of breast events
between the two groups. The authors concluded that eld-
erly patients with small tumours without clinical axillary
involvement may be satisfactorily treated with conserva-
tive surgery and tamoxifen.
Twenty three percent of patients who had an axillary dis-
section had metastatic nodal infiltration. However, only
1.8% of patients who had tumour excision only required
a delayed axillary dissection for clinically overt axillary
disease. These findings suggest that the vast majority of
microscopic axillary nodal metastases are clinically irrele-
vant.
In our patients the prognostic information supplied by
axillary dissection would not have altered management.
Due to resource limitations, before March 2004 patients
received tamoxifen irrespective of hormone receptor sta-
tus and no chemotherapy was offered. In our series 16.4%
of patients had palpable axillary nodes. It stands to reason
that the nodes were microscopically involved in many
more cases. However, the cumulative incidence of
regional recurrence is comparable to that observed by
Martelli et al., [13] mentioned above. The fact that none of
the patients with palpable nodes required axillary dissec-
tion for regional control also confirms the effectiveness of
tamoxifen in controlling these nodes.
Adjuvant tamoxifen treatment substantially improves the
survival of women with oestrogen receptor positive
tumours [35]. Tamoxifen significantly reduced the rate of
treatment failure at local and distant sites, second breast
cancers and the incidence of tumour recurrence after
lumpectomy and breast irradiation [36,37]. Tamoxifen
has also been evaluated as sole treatment of breast cancer
in the elderly and earlier studies suggested that tamoxifen
alone is sufficient treatment [38-40]. Recent meta – anal-
ysis however shows that breast cancer specific survival and
progression-free survival is worse in women treated with
tamoxifen alone [41-45]. We support the notion that
tamoxifen alone is inadequate therapy that should be
reserved for very frail patients.
Compliance with Tamoxifen use was not evaluated in any
of the above mentioned series. One of the reasons for the
low rate of treatment failure in general of our patients may
be the use of adjuvant tamoxifen and the high rate of long
term compliance with its use.
The use of tamoxifen in patients with unknown or nega-
tive hormone receptors is debatable as it may expose
patients to the side effects of the drug without any clinical
benefit [35]. The probability of tumours in the elderly
being oestrogen receptor positive has been reported as
85% [8]. The cost of hormone receptor determination at
our institution is about ten times that of one month's sup-
ply of tamoxifen. It can therefore be argued that it is not
cost effective to determine receptor status in view of isolat-
ing the 15% of patients who will not benefit from
Table 7: Recurrence and survival rates with omission of radiotherapy.
Authors Inclusion 
age
Number 
of 
patients
Local or 
regional recurrence
Local 
recurrence
Regional 
recurrence
Overall 
survival
Hughes et al [15] >70 636 L+T 4% L+T 86%
L+T+R 1% (P < 0.001) L+T+R 87% 
(P = 0.94)
Fyles et al [52] > 50 769 L+T 7.7% L+T 2.5% L+T 93.2%
L+T+R 0.6% 
(P < 0.001)
L+T+R 0.5% 
(p = 0.049
L+T+R 92.8% 
(p = 0.83)
Gruenberger et al [10] >60 356 Q+ A ± C ± T 5.4% Q+ A ± C ± T 82%
Q+ A ± C ± T + R 5.8% Q+ A ± C ± T +R 82.7%
L +T : Lumpectomy and Tamoxifen. L+T+R : Lumpectomy, Tamoxifen and whole breast irradiation
Q: Quadrenectomy. A: axillary clearance R: whole breast irradiation C; CMF. T: TamoxifenPage 6 of 8
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erated in the elderly and might have an advantageous
effect on blood lipid levels and bone mineral density
[4,8,42-44,46,47].
By 2010, the majority of approximately 1.5 million
annual new cases of breast cancer will be diagnosed in
women in countries with limited resources [48]. The chal-
lenges of treating these patients are multiple.
Adjuvant systemic and radiation therapies are increasingly
expensive and careful consideration of cost-efficacy is
needed.
The further life expectancy of South African women
between 70 and 74 is 10.4 years, of women 75 to 79 it is
8 years and for those 80 to 84 it is 5.9 years versus in the
USA 14.8 years, 11.2 years and 8.5 years respectively [7].
This shows that even in a developing country elderly
women may have a substantial further life expectancy and
treatment options should be considered carefully as to not
compromise local or distant disease control.
Compared with the treatment of early breast cancer, the
treatment of advanced breast cancer is more resource
intensive and has poorer outcomes. This highlights the
potential benefit of earlier detection and diagnosis, espe-
cially in countries with limited resources [49].
In a survey investigating the awareness of breast and cervi-
cal cancers among South African women, almost one fifth
of the women had not heard of these cancers, and almost
half were unaware of the breast self-examination tech-
nique. Lower awareness levels were also found in older
and rural women [50]. In our study 48.2% of patients pre-
sented with disease too advanced for conservative treat-
ment, demonstrating the need for earlier detection of
breast cancer in developing countries.
Conclusion
In a country with limited resources, limited surgery and
tamoxifen provide excellent control of breast cancer in the
elderly comparable to results obtained in less resource
restricted environments.
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